Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tay-Sachs disease as a model for screening inborn errors.

M G Blitzer1, G A McDowell

  • 1Department of Pediatrics, University of Maryland School of Medicine, Baltimore.

Clinics in Laboratory Medicine
|September 1, 1992
PubMed
Summary

Carrier screening for genetic metabolic disorders like Tay-Sachs disease (TSD) enables prevention. Identifying at-risk couples through enzyme assays and DNA mutation analysis is crucial for rare diseases with increased gene frequencies in specific populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal blood-pressure trends throughout pregnancy and development of pre-eclampsia in women receiving first-trimester aspirin prophylaxis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Educational innovations in clinical pharmacogenomics.

Clinical pharmacology and therapeutics·2016
Same author

External validity of first-trimester algorithms in the prediction of pre-eclampsia disease severity.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2014
Same author

First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2014
Same author

Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee.

Genetics in medicine : official journal of the American College of Medical Genetics·2001
Same author

Summary of the Association of Professors of Human and Medical Genetics Fourth Annual Workshop.

American journal of medical genetics·1999

Area of Science:

  • Medical Genetics
  • Biochemistry
  • Preventive Medicine

Background:

  • Most inborn errors of metabolism lack treatments, necessitating disease prevention through identification of at-risk couples.
  • Carrier identification relies on enzyme assays or direct gene mutation analysis when the responsible enzyme and gene are known.
  • Screening is most effective for individuals with a family history or within populations with elevated gene frequencies for specific genetic disorders.

Purpose of the Study:

  • To highlight the success of carrier screening for Tay-Sachs disease (TSD) as a model for other inherited metabolic disorders.
  • To emphasize the importance of identifying at-risk populations for genetic disease prevention.
  • To discuss the role of enzyme assays and DNA mutation analysis in carrier detection and prenatal diagnosis.

Related Experiment Videos

Main Methods:

  • Enzyme assays for detecting deficient Hex A activity in Tay-Sachs disease.
  • DNA mutation analysis for precise identification of Tay-Sachs disease gene mutations.
  • Population-specific carrier screening programs, exemplified by the Ashkenazi Jewish community.

Main Results:

  • Tay-Sachs disease (TSD), caused by Hex A deficiency, has a carrier frequency of 1/30 in the Ashkenazi Jewish population, significantly higher than the general population (1/167).
  • Reliable heterozygote detection and prenatal diagnosis of TSD are achievable through enzyme assays and DNA analysis.
  • TSD screening in the Ashkenazi Jewish population serves as a successful prototype for carrier screening in other inherited metabolic disorders.

Conclusions:

  • Carrier screening and prenatal diagnosis have made TSD prevention possible through education and identification of at-risk couples.
  • The TSD model is increasingly relevant for other genetic disorders with elevated frequencies in specific populations, such as cystic fibrosis in Caucasians.
  • Advancements in genetic testing enable more accurate screening and diagnosis, improving the prevention of rare inherited diseases.